释放向组素修饰酶的潜力,用于治疗IBD和CRC
Bing Liang1,2, Yanhong Wang3,4, Jiazhen Xu3,4
1Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China. liangbing518@hotmail.com.
Clinical epigenetics
|September 12, 2023
概括
基素修饰失调是炎症性肠病 (IBD) 和结直肠癌 (CRC) 的关键. 向基因组修饰酶显示为治疗这些胃肠道疾病的治疗策略有前途.
科学领域:
- 胃肠道学和瘤学
- 表观遗传学和分子生物学
背景情况:
- 失调的组素修饰与炎症性肠病 (IBD) 和结肠直肠癌 (CRC) 的病原发生有关.
- 在IBD和CRC中,慢性炎症与改变的组织蛋白修饰有关,影响疾病的发展和进展.
- 肠道微生物群影响宿主基因表达和基因素修饰,影响肠道平衡和免疫反应.
研究的目的:
- 审查潜在的治疗干预措施,以向IBD和CRC中的基因组修饰酶.
- 分析临床试验,研究用于IBD和CRC治疗的基因组修饰酶抑制剂.
- 探索针对胃肠道疾病的表观遗传修饰的最新进展,局限性和未来研究方向.
主要方法:
- 科学文章和临床试验数据的文献综述.
- 分析基因组修饰酶和染色质修饰在IBD和CRC中的作用.
- 检查涉及基因组修饰酶抑制剂的治疗策略.
主要成果:
- 基因组修饰失调是IBD和CRC的共同特征.
- 在IBD和CRC的临床试验中,正在探索基因组修饰酶的抑制剂.
- 了解这些表观遗传机制提供了新的治疗途径.
结论:
- 向基因组修饰酶是IBD和CRC的一种有前途的治疗策略.
- 对基因组修饰酶及其染色质修饰的功能进行进一步研究对于开发有效的治疗方法至关重要.
- 评估这些表观遗传抑制剂的临床试验对于验证它们在胃肠道疾病中的有效性和安全性至关重要.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
190
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
190
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
168
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
168
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Ulcerative Colitis in IBD
168
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
168
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
354
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
354


